{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T16:29:28Z","timestamp":1753892968797,"version":"3.41.2"},"reference-count":49,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,8,27]],"date-time":"2024-08-27T00:00:00Z","timestamp":1724716800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82171338"],"award-info":[{"award-number":["82171338"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006606","name":"Natural Science Foundation of Tianjin","doi-asserted-by":"publisher","award":["22JCYBJC00700"],"award-info":[{"award-number":["22JCYBJC00700"]}],"id":[{"id":"10.13039\/501100006606","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Public Health"],"abstract":"<jats:sec><jats:title>Objective<\/jats:title><jats:p>We investigated the risk factors associated with severe or critical Coronavirus disease 2019 (COVID-19) infection due to the Omicron variant in patients with myasthenia gravis (MG) and determined the potential effect of COVID-19 on myasthenic exacerbation during the Omicron pandemic.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>This retrospective study included 287 patients with MG in Tianjin, China. Clinical data of the patients were collected using electronic questionnaires, databases, and clinical records.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The overall infection rate was 84.7%. Advanced age, comorbidities, generalized phenotype, and MG instability were drivers of COVID-19 severity, and post-COVID-19 myasthenic exacerbation. The concurrent use of a steroid-sparing agent did not affect COVID-19 susceptibility or severity. It did lower the risk of myasthenic exacerbation after COVID-19 infection. Patients with severe COVID-19 experienced myasthenic exacerbation earlier than patients with non-severe infection (<jats:italic>p<\/jats:italic>\u2009&amp;lt;\u20090.001). The severity of COVID-19 (Hazards Ratio\u2009=\u20093.04, 95% CI: 1.41\u20136.54, <jats:italic>p<\/jats:italic>\u2009=\u20090.004) and the clinical phenotype (Hazards Ratio\u2009=\u20093.29, 95% CI: 1.63\u20136.63, <jats:italic>p<\/jats:italic>\u2009&amp;lt;\u20090.001) emerged as independent risk factors for early MG exacerbation.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Generally, patients with MG appear to be susceptible to the Omicron strains. Immunotherapy for MG did not increase COVID-19 susceptibility or severity. We do not advocate an immediate cessation of ongoing immunosuppressive treatments once a COVID-19 infection is diagnosed. Instead, a judicious evaluation of the risks and benefits, tailored to each individual, is recommended.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fpubh.2024.1421211","type":"journal-article","created":{"date-parts":[[2024,8,27]],"date-time":"2024-08-27T04:38:32Z","timestamp":1724733512000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Clinical features of COVID-19 infection in patients with myasthenia gravis: a real-world retrospective study"],"prefix":"10.3389","volume":"12","author":[{"given":"Hui-Ning","family":"Li","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiao-Na","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ying-Hui","family":"Qin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rui","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wen-Yue","family":"Guo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiao-Yu","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mo-Li","family":"Fan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lin-Jie","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuan","family":"Qi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fu-Dong","family":"Shi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chun-Sheng","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2024,8,27]]},"reference":[{"year":"2021","key":"ref1"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"2268","DOI":"10.1056\/NEJMc2008597","article-title":"Neurologic features in severe SARS-CoV-2 infection","volume":"382","author":"Helms","year":"2020","journal-title":"N Engl J Med"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"e1060","DOI":"10.1212\/WNL.0000000000009937","article-title":"Neurologic manifestations in hospitalized patients with COVID-19: the ALBACOVID registry","volume":"95","author":"Romero-S\u00e1nchez","year":"2020","journal-title":"Neurology"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1001\/jamaneurol.2020.1127","article-title":"Neurologic manifestations of hospitalized patients with coronavirus disease 2019 in Wuhan, China","volume":"77","author":"Mao","year":"2020","journal-title":"JAMA Neurol"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"1396642","DOI":"10.3389\/fneur.2024.1396642","article-title":"Guillain-Barre syndrome and link with COVID-19 infection and vaccination: a review of literature","volume":"15","author":"Valaparla","year":"2024","journal-title":"Front Neurol"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"2574","DOI":"10.1056\/NEJMc2009191","article-title":"Guillain-Barr\u00e9 syndrome associated with SARS-CoV-2","volume":"382","author":"Toscano","year":"2020","journal-title":"N Engl J Med"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1007\/s00415-022-11472-6","article-title":"New-onset myasthenia gravis after SARS-CoV-2 infection: case report and literature review","volume":"270","author":"Silva","year":"2020","journal-title":"Front Neurol"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1212\/WNL.0000000000009566","article-title":"COVID-19 and neuromuscular disorders","volume":"94","author":"Guidon","year":"2020","journal-title":"Neurology"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"1251","DOI":"10.1007\/s00415-018-8751-9","article-title":"Myasthenia gravis and infectious disease","volume":"265","author":"Gilhus","year":"2018","journal-title":"J Neurol"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1038\/nri2527","article-title":"Antiviral immune responses: triggers of or triggered by autoimmunity?","volume":"9","author":"M\u00fcnz","year":"2009","journal-title":"Nat Rev Immunol"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1002\/mus.26689","article-title":"Factors associated with acute exacerbations of myasthenia gravis","volume":"60","author":"Gummi","year":"2019","journal-title":"Muscle Nerve"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1097\/CND.0000000000000316","article-title":"Myasthenic syndrome caused by hydroxychloroquine used for COVID-19 prophylaxis","volume":"22","author":"Koc","year":"2020","journal-title":"J Clin Neuromuscul Dis"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"849","DOI":"10.4081\/reumatismo.2015.849","article-title":"Myasthenia gravis due to hydroxychloroquine","volume":"67","author":"Varan","year":"2015","journal-title":"Reumatismo"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1002\/mus.26918","article-title":"COVID -19 in patients with myasthenia gravis","volume":"62","author":"Anand","year":"2020","journal-title":"Muscle Nerve"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1002\/mus.27919","article-title":"COVID-19 infection in myasthenia gravis: clinical course and outcomes","volume":"68","author":"Thomas","year":"2023","journal-title":"Muscle Nerve"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"e2109","DOI":"10.1212\/WNL.0000000000011669","article-title":"Impact of coronavirus disease 2019 in a French cohort of myasthenia gravis","volume":"96","author":"Sol\u00e9","year":"2021","journal-title":"Neurology"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"e2789","DOI":"10.1002\/brb3.2789","article-title":"COVID-19 and myasthenia gravis: a review of neurological implications of the SARS-COV-2","volume":"12","author":"Shah","year":"2022","journal-title":"Brain Behav"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"116803","DOI":"10.1016\/j.jns.2020.116803","article-title":"Guidance for the management of myasthenia gravis (MG) and Lambert-Eaton myasthenic syndrome (LEMS) during the COVID-19 pandemic","volume":"412","author":"Jacob","year":"2020","journal-title":"J Neurol Sci"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"970","DOI":"10.1016\/S1474-4422(20)30413-0","article-title":"COVID-19-associated risks and effects in myasthenia gravis (CARE-MG)","volume":"19","author":"Muppidi","year":"2020","journal-title":"Lancet Neurol"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1016\/S1474-4422(21)00297-0","article-title":"Epidemiology, diagnostics, and biomarkers of autoimmune neuromuscular junction disorders","volume":"21","author":"Punga","year":"2022","journal-title":"Lancet Neurol"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"1487","DOI":"10.1212\/wnl.52.7.1487","article-title":"Myasthenia gravis activities of daily living profile","volume":"52","author":"Wolfe","year":"1999","journal-title":"Neurology"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1002\/mus.22140","article-title":"MG-ADL: still a relevant outcome measure","volume":"44","author":"Muppidi","year":"2011","journal-title":"Muscle Nerve"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1002\/mus.23988","article-title":"Minimal clinically important difference in myasthenia gravis: outcomes from a randomized trial","volume":"49","author":"Katzberg","year":"2014","journal-title":"Muscle Nerve"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1093\/aje\/kwx299","article-title":"Separation in logistic regression: causes, consequences, and control","volume":"187","author":"Mansournia","year":"2018","journal-title":"Am J Epidemiol"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"2969","DOI":"10.1007\/s10072-024-07518-4","article-title":"COVID-19 in patients with myasthenia gravis: a single-center retrospective study in China","volume":"45","author":"Li","year":"2024","journal-title":"Neurol Sci"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"3157","DOI":"10.2147\/JIR.S419307","article-title":"Clinical characteristics of myasthenia gravis patients with COVID-19 in Guangxi, China: a case-control study","volume":"16","author":"Zhou","year":"2023","journal-title":"J Inflamm Res"},{"year":"2022","key":"ref27"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00415-022-11389-0","article-title":"Risk and course of COVID-19 in immunosuppressed patients with myasthenia gravis","volume":"270","author":"Stascheit","year":"2023","journal-title":"J Neurol"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"1146","DOI":"10.1038\/s41590-020-0779-1","article-title":"The dynamic changes in cytokine responses in COVID-19: a snapshot of the current state of knowledge","volume":"21","author":"Buszko","year":"2020","journal-title":"Nat Immunol"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"1637","DOI":"10.1016\/S0140-6736(21)00676-0","article-title":"Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial","volume":"397","year":"2021","journal-title":"Lancet"},{"key":"ref31","first-page":"39","article-title":"Long-term (180-day) outcomes in critically ill patients with COVID-19 in the REMAP-CAP randomized clinical trial","volume-title":"JAMA","author":"Higgins","year":"2023"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"1491","DOI":"10.1056\/NEJMoa2100433","article-title":"Interleukin-6 receptor antagonists in critically ill patients with Covid-19","volume":"384","author":"Gordon","year":"2021","journal-title":"N Engl J Med"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1038\/s41582-020-0385-8","article-title":"Neurological immunotherapy in the era of COVID-19 - looking for consensus in the literature","volume":"16","author":"Korsukewitz","year":"2020","journal-title":"Nat Rev Neurol"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1016\/j.clml.2020.08.017","article-title":"Persistent COVID-19 pneumonia and failure to develop anti-SARS-CoV-2 antibodies during rituximab maintenance therapy for follicular lymphoma","volume":"20","author":"Yasuda","year":"2020","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"3384","DOI":"10.1111\/ene.14690","article-title":"COVID-19 in multiple sclerosis patients: susceptibility, severity risk factors and serological response","volume":"28","author":"Zabalza","year":"2021","journal-title":"Eur J Neurol"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1111\/ene.14521","article-title":"EAN consensus statement for management of patients with neurological diseases during the COVID-19 pandemic","volume":"28","author":"von Oertzen","year":"2021","journal-title":"Eur J Neurol"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"1738","DOI":"10.1002\/acn3.51408","article-title":"DMTs and Covid-19 severity in MS: a pooled analysis from Italy and France","volume":"8","author":"Sormani","year":"2021","journal-title":"Ann Clin Transl Neurol"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"938","DOI":"10.1002\/acn3.51342","article-title":"Multiple sclerosis, rituximab, and COVID-19","volume":"8","author":"Langer-Gould","year":"2021","journal-title":"Ann Clin Transl Neurol"},{"key":"ref39","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.3389\/fneur.2020.01053","article-title":"Myasthenia gravis and COVID-19: clinical characteristics and outcomes","volume":"11","author":"Camelo-Filho","year":"2020","journal-title":"Front Neurol"},{"key":"ref40","doi-asserted-by":"publisher","first-page":"102120","DOI":"10.1016\/j.msard.2020.102120","article-title":"COVID-19 in a MS patient treated with ocrelizumab: does immunosuppression have a protective role?","volume":"42","author":"Novi","year":"2020","journal-title":"Mult Scler Relat Disord"},{"key":"ref41","doi-asserted-by":"publisher","first-page":"577528","DOI":"10.1016\/j.jneuroim.2021.577528","article-title":"Low-dose rituximab treatment for new-onset generalized myasthenia gravis","volume":"354","author":"Li","year":"2021","journal-title":"J Neuroimmunol"},{"key":"ref42","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1016\/j.nmd.2023.02.005","article-title":"Immunological response after SARS-CoV-2 infection and mRNA vaccines in patients with myasthenia gravis treated with rituximab","volume":"33","author":"Damato","year":"2023","journal-title":"Neuromuscul Disord"},{"key":"ref43","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1080\/14737175.2022.2057223","article-title":"Immunomodulatory effects and clinical benefits of intravenous immunoglobulin in myasthenia gravis","volume":"22","author":"Dalakas","year":"2022","journal-title":"Expert Rev Neurother"},{"key":"ref44","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/j.thromres.2020.04.041","article-title":"Confirmation of the high cumulative incidence of thrombotic complications in critically ill ICU patients with COVID-19: an updated analysis","volume":"191","author":"Klok","year":"2020","journal-title":"Thromb Res"},{"key":"ref45","doi-asserted-by":"publisher","first-page":"1141983","DOI":"10.3389\/fimmu.2023.1141983","article-title":"Safety of COVID-19 vaccine in patients with myasthenia gravis: a self-controlled case series study","volume":"14","author":"Ruan","year":"2023","journal-title":"Front Immunol"},{"key":"ref46","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1016\/j.immuni.2020.11.006","article-title":"Germinal center and Extrafollicular B cell responses in vaccination, immunity, and autoimmunity","volume":"53","author":"Ra","year":"2020","journal-title":"Immunity"},{"key":"ref47","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1186\/s41983-022-00516-3","article-title":"The relationship between myasthenia gravis and COVID-19: a systematic review","volume":"58","author":"Tugasworo","year":"2022","journal-title":"Egypt J Neurol Psychiatry Neurosurg"},{"key":"ref48","doi-asserted-by":"publisher","first-page":"872","DOI":"10.7326\/L20-1298","article-title":"MuSK antibody-associated myasthenia gravis with SARS-CoV-2 infection: a case report","volume":"174","author":"Muhammed","year":"2021","journal-title":"Ann Intern Med"},{"key":"ref49","doi-asserted-by":"publisher","first-page":"3537","DOI":"10.1111\/ene.14721","article-title":"Myasthenia gravis associated with anti-MuSK antibodies developed after SARS-CoV-2 infection","volume":"28","author":"Assini","year":"2021","journal-title":"Eur J Neurol"}],"container-title":["Frontiers in Public Health"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpubh.2024.1421211\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,27]],"date-time":"2024-08-27T04:38:36Z","timestamp":1724733516000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpubh.2024.1421211\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,27]]},"references-count":49,"alternative-id":["10.3389\/fpubh.2024.1421211"],"URL":"https:\/\/doi.org\/10.3389\/fpubh.2024.1421211","relation":{},"ISSN":["2296-2565"],"issn-type":[{"type":"electronic","value":"2296-2565"}],"subject":[],"published":{"date-parts":[[2024,8,27]]},"article-number":"1421211"}}